Evidence map›Paper›PMID 40434590›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Antimicrobial activity of lefamulin against pathogens most commonly causing community-acquired pneumonia: results from the China antimicrobial surveillance network in 2020-2022.

Li Ding, Siquan Shen, Renru Han, Dandan Yin, Yang Yang, Shi Wu, Demei Zhu, Yan Guo, Fupin Hu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li DingInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Siquan ShenInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Renru HanInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Dandan YinInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Yang YangInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Shi WuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Demei ZhuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China.
Yan GuoInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China. guoyan@fudan.edu.cn.
Fupin HuInstitute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd, Shanghai, 200040, China. hufupin@fudan.edu.cn.

Funding

China Antimicrobial Surveillance Network 2018QD100Shanghai Antimicrobial Surveillance Network 3030231003
6 · The paper itself

Abstract

objectivesLefamulin is a novel pleuromutilin antibiotic used for the treatment of community-acquired pneumonia (CAP). This study aimed to evaluate the in vitro antimicrobial activity of lefamulin against clinical isolates obtained from China.

methods1,052 non-duplicate isolates included the following isolates: Streptococcus pneumoniae (n = 529), Staphylococcus aureus (n = 306), Haemophilus influenzae (n = 121), Moraxella catarrhalis (n = 81), and Mycoplasma pneumoniae (n = 15), were collected from 70 hospitals participating in the China Antimicrobial Surveillance Network (CHINET) between October 1, 2020, and November 30, 2022. Minimum inhibitory concentrations were determined using the broth microdilution method in accordance with the standards set by the Clinical and Laboratory Standards Institute.

resultsIn vitro, S. pneumoniae exhibited 100% sensitivity to lefamulin, with MIC

conclusionsLefamulin exhibited potent in vitro activity against prevalent and drug-resistant pathogens associated with CAP in China.

Indexed as

Anti-Bacterial AgentsBacteriaCommunity-Acquired InfectionsDiterpenesPneumonia, BacterialPolycyclic CompoundsChinaCommunity-Acquired PneumoniaHaemophilus influenzaeHumansMicrobial Sensitivity TestsMoraxella catarrhalisMycoplasma pneumoniaeStaphylococcus aureusStreptococcus pneumoniaeThioglycolatesAnti-Bacterial AgentsDiterpeneslefamulinPolycyclic CompoundsThioglycolatesHaemophilus influenzaeLefamulinMycoplasma pneumoniaeStaphylococcus aureusStreptococcus pneumoniae

Identifiers

PMID40434590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.